Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis

Autoři: Md Asiful Islam aff001;  Sayeda Sadia Alam aff002;  Shoumik Kundu aff002;  A. H. M. Safayet Ullah Prodhan aff002;  Shahad Saif Khandker aff002;  Tatiana Reshetnyak aff003;  Przemysław J. Kotyla aff004;  Rosline Hassan aff001;  Tareq Hossan aff002
Působiště autorů: Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia aff001;  Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka , Bangladesh aff002;  Department of Systemic Rheumatic Disease, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia aff003;  Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty in Katowice, Medical University of Silesia, Katowice, Poland aff004
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227836


Behçet’s disease (BD) is a multifactorial systemic inflammatory disease of unknown aetiology characterised by several clinical manifestations including vascular involvements (i.e., both arterial and venous thrombosis). Antiphospholipid antibodies (aPLs)—including anticardiolipin (aCL), anti-β2-glycoprotein I (β2-GPI) antibodies and lupus anticoagulant (LA) are detected in systemic autoimmune diseases which contribute to thrombosis. The aim of this systematic review and meta-analysis was to evaluate the prevalence of aPLs in patients with BD as compared to controls. A protocol was registered in PROSPERO (Registration No. CRD42018088125) and a systematic literature search was conducted through PubMed, Web of Science, Embase, Scopus and ScienceDirect databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects model. Quality assessment was carried out by using the modified 9-star Newcastle-Ottawa Scale (NOS). Publication bias was evaluated via visualisation of contour- enhanced and trim and fill funnel plots along with Begg's and Egger's tests. We included ten case-control studies (a total of 999 participants from 380 BD patients and 619 controls) based on the inclusion criteria. The prevalence of aCL (OR: 12.10, 95% CI: 5.15–28.41, p<0.00001) and anti-β2-GPI antibodies (OR: 23.57, 95% CI: 1.31–423.63, p = 0.03) were statistically significant, however, the prevalence of LA was not significant (OR: 13.77, 95% CI: 0.65–293.59, p = 0.09). The results remained statistically significant from different sensitivity analyses which represented the robustness of this meta-analysis. According to the NOS, 50.0% of the studies were considered as of high methodological quality (low risk of bias). No significant publication bias was detected from contour-enhanced and trim and fill funnel plots or Begg's and Egger’s tests. This meta-analysis established that there is a significantly high prevalence of aPLs (i.e., aCL and anti-β2-GPI antibodies) in patients with BD when compared to controls.

Klíčová slova:

Case-control studies – Database searching – Deep vein thrombosis – Enzyme-linked immunoassays – Metaanalysis – Publication ethics – Systematic reviews – Thrombosis


1. Alpsoy E., Donmez L., Onder M., Gunasti S., Usta A., Karincaoglu Y., et al., Clinical features and natural course of Behçet’s disease in 661 cases: a multicentre study. Br J Dermatol 157 (2007) 901–6. doi: 10.1111/j.1365-2133.2007.08116.x 17711526

2. International study group for Behcet's disease, Criteria for Diagnosis of Behcet's Disease. Lancet 335 (1990) 1078–80. 1970380

3. Yıldız M., Köker O., Adrovic A., Şahin S., Barut K., Kasapçopur Ö., Pediatric Behçet's disease-clinical aspects and current concepts. European journal of rheumatology (2019) 1–10. doi: 10.5152/eurjrheum.2019.19121 31556871

4. Greco A., De Virgilio A., Ralli M., Ciofalo A., Mancini P., Attanasio G., et al., Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17 (2018) 567–75. doi: 10.1016/j.autrev.2017.12.006 29631062

5. Leccese P., Alpsoy E., Behçet's disease: An overview of etiopathogenesis. Front Immunol 10 (2019) 1–8. doi: 10.3389/fimmu.2019.00001 31134098

6. Angioni M.M., Piga M., Paladini F., Lai S., Erre G.L., Floris A., et al., AIF-1 gene does not confer susceptibility to Behçet’s disease: Analysis of extended haplotypes in Sardinian population. PLoS One 13 (2018) e0204250. doi: 10.1371/journal.pone.0204250 30252881

7. Khabbazi A., Vahedi L., Ghojazadeh M., Pashazadeh F., Khameneh A., Association of HLA-B27 and Behcet’s disease: a systematic review and meta-analysis. Auto Immun Highlights 10 (2019) 1–8. doi: 10.1186/s13317-019-0110-z 30891643.

8. Cheng Y., Zhao X., Chen Y., Li Y., Jia R., Zhu L., et al., Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet’s Disease. PLoS One 13 (2018) e0199047. doi: 10.1371/journal.pone.0199047 29902281

9. Davatchi F., Chams-Davatchi C., Shams H., Shahram F., Nadji A., Akhlaghi M., et al., Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 13 (2017) 57–65. doi: 10.1080/1744666X.2016.1205486 27351485

10. Ramos-Casals M., Brito-Zerón P., Kostov B., Sisó-Almirall A., Bosch X., Buss D., et al., Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev 14 (2015) 670–9. doi: 10.1016/j.autrev.2015.03.008 25842074

11. Leonardo N.M., McNeil J., Behçet’s disease: is there geographical variation? A review far from the Silk Road. Int J Rheumatol 2015 (2015) 1–7. doi: 10.1155/2015/945262 26798344

12. Maldini C., Druce K., Basu N., LaValley M.P., Mahr A., Exploring the variability in Behçet’s disease prevalence: a meta-analytical approach. Rheumatology 57 (2017) 185–95. doi: 10.1093/rheumatology/kew486 28339670

13. Calamia K.T., Schirmer M., Melikoglu M., Major vessel involvement in Behçet's disease: an update. Curr Opin Rheumatol 23 (2011) 24–31. doi: 10.1097/BOR.0b013e3283410088 21124084

14. Wu C.-Y., Yu H.-S., Chai C.-Y., Wen Y.-H., Wu S.-S., Chang Y.-P., et al., Increased ischemic stroke risk in patients with Behçet’s disease: A nationwide population-based cohort study. PLoS One 14 (2019) e0218652. doi: 10.1371/journal.pone.0218652 31237911

15. Emmi G., Silvestri E., Squatrito D., Amedei A., Niccolai E., D’Elios M.M., et al., Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J 13 (2015) 1–10. doi: 10.1186/1477-9560-13-1 25883536

16. Becatti M., Emmi G., Silvestri E., Bruschi G., Ciucciarelli L., Squatrito D., et al., Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation 133 (2016) 302–11. doi: 10.1161/CIRCULATIONAHA.115.017738 26585672

17. Islam M.A., Alam F., Cavestro C., Calcii C., Sasongko T.H., Levy R.A., et al., Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. Autoimmun Rev 17 (2018) 755–67. doi: 10.1016/j.autrev.2018.01.025 29885542

18. Islam M.A., Alam F., Wong K.K., Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta-analysis. Autoimmun Rev 16 (2017) 512–22. doi: 10.1016/j.autrev.2017.03.005 28279839

19. Islam M., Alam F., Kamal M.A., Gan S.H., Sasongko T.H., Wong K.K., Presence of anticardiolipin antibodies in patients with dementia: a systematic review and meta-analysis. Front Aging Neurosci 9 (2017) 1–12. doi: 10.3389/fnagi.2017.00001 28824414

20. Al-Dalaan A., Al-Ballaa S., Al-Janadi M., Bohlega S., Bahabri S., Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behçets disease. Clin Rheumatol 12 (1993) 28–30. doi: 10.1007/bf02231554 8467608

21. Yelnik C., Urbanski G., Drumez E., Sobanski V., Maillard H., Lanteri A., et al., Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 26 (2017) 163–9. doi: 10.1177/0961203316657433 27432808

22. Kang H.J., Lee Y.-W., Han S.H., Cho H.C., Lee K.M., Anticardiolipin and anti-β2-glycoprotein I antibodies in Behcet's disease. J Korean Med Sci 13 (1998) 400–4. doi: 10.3346/jkms.1998.13.4.400 9741545

23. Musabak U., Baylan O., Cetin T., Yesilova Z., Sengul A., Saglam K., et al., Lipid profile and anticardiolipin antibodies in Behcet's disease. Arch Med Res 36 (2005) 387–92. doi: 10.1016/j.arcmed.2005.03.019 15950080

24. Rajaee A., Nazarinia M.A., Hakim S.M., Amini M., Ayatollahi M., Ghaderi A., Anticardiolipin Antibody in Patients with Behçet's Disease with and without Vascular Thrombosis. Iran J Immunol 1 (2004) 111–7.

25. Famularo G., Antonelli S., Barracchini A., Menichelli M., Nicotra G.C., Minisola G., Catastrophic antiphospholipid syndrome in a patient with Behçet's disease. Scand J Rheumatol 31 (2002) 100–2. doi: 10.1080/03009740252937630 12109643

26. Klok A.-M., Geertzen R., Rothova A., Baarsma G.S., Kijlstra A., Anticardiolipin antibodies in uveitis. Curr Eye Res 11 (1992) 209–13. doi: 10.3109/02713689208999535 1424747

27. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al., Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283 (2000) 2008–12. doi: 10.1001/jama.283.15.2008 10789670

28. Moher D., Liberati A., Tetzlaff J., Altman D.G., Prisma Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6 (2009) 1–6. doi: 10.1371/journal.pmed.1000097 19621072

29. Islam M.A., Khandker S.S., Alam S.S., Kotyla P., Hassan R., Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev (2019) doi: 10.1016/j.autrev.2019.102392 31520805

30. Qiu T.T., Zhang C., Zhao H.W., Zhou J.W., Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev 16 (2017) 136–45. doi: 10.1016/j.autrev.2016.12.005 27988429

31. Review manager (RevMan)[computer program] Version 5.3.5, Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration (2014)

32. Viechtbauer W., Conducting meta-analyses in R with the metafor package. J Stat Softw 36 (2010) 1–48. doi: 10.1186/s13643-019-1118-1 PMID: 31399073

33. EL-Nakeeb S.M., Ragheb A.M., El-Baz H., Assessment of Anticardiolipin antibodies, Circulating Lupus anticoagulant, Protein C, Protein S, Antithrombin III & Activated Protein C Resistance and Their Relation to Thomboembolic and Other Clinical Manifestations in Behcet's Disease. Egypt J Hosp Med 24 (2006) 539–47.

34. Bergman R., Lorber M., Lerner M., Brik R., Friedman‐Birnbaum R., Anticardiolipin antibodies in Behçet's disease. J Dermatol 17 (1990) 164–7. doi: 10.1111/j.1346-8138.1990.tb01619.x 2355142

35. Hughes J.R., Davies J.A., Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events. Thromb Res 89 (1998) 101–6. doi: 10.1016/s0049-3848(97)00299-5 9622037

36. El-Ageb E., Al-Maini M., Al-Shukaily A., Al-Farsi Y., Richens E., Clinical features of Behçet's disease in patients in the Sultanate of Oman; the significance of antiphospholipid antibodies? Rheumatol Int 21 (2002) 176–81. doi: 10.1007/s00296-001-0157-8 11958433

37. Espinosa G., Font J., Tàssies D., Vidaller A., Deulofeu R., López-Soto A., et al., Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112 (2002) 37–43. doi: 10.1016/s0002-9343(01)01048-8 11812405

38. Ji H.G., Bang D.S., Lee S., Cha Y.S., Anticardiolipin antibodies in patients with Behçet's disease. Ann Dermatol 4 (1992) 1–8.

39. Zivkovic M., Zlatanovic M., Zlatanovic G., Djordjevic-Jocic J., Cekic S., Anticardiolipin antibodies in patients with Behcet’s disease. Bosn J Basic Med Sci 11 (2011) 58–61. doi: 10.17305/bjbms.2011.2625 21342144

40. Islam M.A., Alam F., Teguh Haryo S., Siew Hua G., Antiphospholipid antibody-mediated thrombotic mechanisms in antiphospholipid syndrome: towards pathophysiology-based treatment. Curr Pharm Des 22 (2016) 4451–69. doi: 10.2174/1381612822666160527160029 27229722

41. Erol S., Hasanzade H., Ciftci F., Dastan A.O., Ciledag A., Gulbay B.E., et al., Clinical characteristics and outcome of patients with Behçet’s Disease and thrombosis. Eur Respir J 52 (2018) PA3129.

42. Hamzaoui A., Jaziri F.S., TB, Houman M., Hamzaoui A., Khanfir M., Lamloum M., Comparison of clinical features of Behcet disease according to age in a Tunisian cohort. Acta Med Iran 52 (2014) 748–51. 25369008

43. Hull R., Harris E., Gharavi A., Tincani A., Asherson R., Valesini G., et al., Anticardiolipin antibodies: occurrence in Behçet's syndrome. Ann Rheum Dis 43 (1984) 746–8. doi: 10.1136/ard.43.5.746 6497467

44. Hampton K., Chamberlian M., Menon D., Davies J., Coagulation and fibrinolytic activity in Behcet's disease. Thromb Haemost 66 (1991) 292–4. 1745999

45. Haznedaroǧlu I.C., Ozcebe O., Celik I., Dündar S., Kirazh Ş., Haemostatic markers of procoagulant imbalance in Behcet's disease. Eur J Haematol 57 (1996) 107–8. doi: 10.1111/j.1600-0609.1996.tb00499.x 8698121

46. El-Ghobashy N., El-Garf K., Abdo M., Arterial aneurysms in Behçet’s disease patients: Frequency, clinical characteristics and long-term outcome. Egypt Rheumatol 1 (2018)

47. Liew J., Ghetie D., Hosmer D., Sibley C., Concurrent pulmonary artery aneurysms and intracardiac thrombus in a Caucasian man with Behçet’s disease: case report and literature review. Mod Rheumatol Case Rep 2 (2018) 97–103.

48. Chung M.H., Lee H.G, Kwon S.S, Kim Y.S, Park S.H, Pulmonary arterial aneurysms in primary antiphospholipid antibody syndrome. J Comput Assist Tomogr 26 (2002) 608–12. doi: 10.1097/00004728-200207000-00023 12218828

49. Duftner C., Seiler R., Dejaco C., Chemelli-Steingruber I., Schennach H., Klotz W., et al., Antiphospholipid antibodies predict progression of abdominal aortic aneurysms. PLoS One 9 (2014) e99302. doi: 10.1371/journal.pone.0099302 24979700

50. Islam A.M., Alam F., Kamal M.A., Kah Keng W., Teguh Haryo S., Siew Hua G., ‘Non-criteria’neurologic manifestations of antiphospholipid syndrome: a hidden kingdom to be discovered. CNS Neurol Disord Drug Targets 15 (2016) 1253–65. doi: 10.2174/1871527315666160920122750 27658514

51. Islam M.A., Alam F., Gan S.H., Cavestro C., Wong K.K., Coexistence of antiphospholipid antibodies and cephalalgia. Cephalalgia 38 (2018) 568–80. doi: 10.1177/0333102417694881 28952322

52. Elezoglou A., Kafasi N., Kaklamanis P., Theodossiadis P., Kapsimali V., Choremi E., et al., Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol 25 (2007) 65–9. 17949554

53. Djaballah-Ider F., Djaballah A., Djeraba Z., Chaib S., Touil-Boukoffa C., Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment. Inflammopharmacology doi: 10.1007/s10787-019-00576-7 30721371

54. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295–306. doi: 10.1111/j.1538-7836.2006.01753.x 16420554

55. Devreese K., Ortel T., Pengo V., de Laat B., Antibodies S.o.L.A.A., Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 16 (2018) 809–13. doi: 10.1111/jth.13976 29532986

Článek vyšel v časopise


2020 Číslo 1